Ovarian Rejuvenation in Infertile Women with Low Anti-Müllerian Hormone Using Peripheral Blood–Derived Stem Cell Techniques

References

[1] B. Choi, Clinical management of poor ovarian response: Current approaches and future directions. Reproductive Biology & Endocrinology, 2021, 1–12.

[2] O. Eze & J.N. Okafor, Socioeconomic inequalities and access to assisted reproductive technology in Sub-Saharan Africa. International Journal of Gynecology & Obstetrics, 2023, 120–128.

[3] R. Linden & M. Barad, Androgen and growth hormone supplementation in poor responders: A meta-analysis. Reproductive Biology & Endocrinology, 2021.

[4] J.O. Eke & C. Okonkwo, Cultural and ethical dilemmas in oocyte donation: Perspectives from Nigeria. African Bioethics Review, 2022, 59–73.

[5] P. Sharma & S. Patel, Regenerative medicine in gynecology: Current trends and future prospects. Frontiers in Reproductive Health, 2023, 11–24.

[6] S. Ali, Stem cell-based therapeutic strategies for premature ovarian insufficiency and infertility: A focus on aging. Cells, 2022.

[7] M. Martirosyan, Stem-cell-derived extracellular vesicles: Unlocking new possibilities for treating diminished ovarian reserve. Life, 2023.

[8] S. Jain & M. Jain, Ovarian rejuvenation—Fact or fiction? Human Reproduction, 2024.

[9] Z. Zafeiri, Anti-Müllerian hormone and pregnancy after autologous hematopoietic stem cell transplantation for multiple sclerosis. PLOS ONE, 2023.

[10] M. Mashayekhi, Intra-ovarian transplantation of adipose-derived MSCs: Phase I clinical trial. Journal of Ovarian Research, 2021.

[11] L. Cacciottola, Use of mesenchymal stem cells to enhance or restore fertility potential. Human Reproduction Open, 2023.

[12] K. Bahrehbar, Embryonic stem cells-derived mesenchymal stem cells do not differentiate into ovarian cells but improve ovarian function in POF mice. Biochemical and Biophysical Research Communications, 2022, 92–98.

[13] K. Grettka, Ovarian stem cells for women’s infertility: State of the art. Biomedicines, 2024.

[14] L. Wang & J. Chen, Menstrual Blood-Derived Stem Cells Promote Follicular Development in Women with Diminished Ovarian Reserve. Stem Cell Research & Therapy, 2023.

[15] S. Ahmed & R. Patel, Exosome-Based Therapy in Female Reproductive Disorders: Emerging Evidence from Preclinical Studies. Journal of Ovarian Research, 2024.

[16] Y. Geng, Stem Cell-Derived Extracellular Vesicles: A Novel and Potential Remedy for Primary Ovarian Insufficiency. Frontiers in Cell & Developmental Biology, 2023.

[17] X. Li & H. Zhao, Exosomal miR-144-5p from Bone Marrow Mesenchymal Stem Cells Enhances Ovarian Function in Chemotherapy-Induced POI Rats. Laboratory Investigation, 2022, 455–467.

[18] L. Wang & J. Chen, Menstrual Blood-Derived Stem Cells Promote Follicular Development in Women with Diminished Ovarian Reserve. Stem Cell Research & Therapy, 2023.

[19] Z. Chen & Z. Zafeiri, Anti-Müllerian Hormone and Pregnancy After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. PLOS ONE, 2023.

[20] N. Pellicer & S. Herraiz, Treatment Potential of Bone Marrow-Derived Stem Cells in Women with Diminished Ovarian Reserves. Current Opinion in Obstetrics & Gynecology, 2020, 156–164.

[21] N. Singh & J. Liu, Trial of Autologous Marrow-Derived Stem Cell Ovarian Transplantation (TAMSCOT) in Young Infertile Women with Diminished Ovarian Reserve. Human Reproduction, 2021.

[22] S. Ali & R. Patel, Stem Cell-Based Therapeutic Strategies for Premature Ovarian Insufficiency and Infertility: A Focus on Aging. Cells, 2022.

[23] L. Cacciottola & H. Liu, Use of Mesenchymal Stem Cells to Enhance or Restore Fertility Potential. Human Reproduction Open, 2023.

[24] H. Liu & T. Kim, Human Amnion-Derived Mesenchymal Stem Cells Improve Reproductive Function in Diminished Ovarian Reserve Models. Stem Cell Research & Therapy, 2021.

[25] F. Fàbregues & J. Cho, In Vitro Follicular Activation and MSC Therapy in Diminished Ovarian Reserve. Frontiers in Endocrinology, 2021.

[26] M. Mashayekhi & L. Cacciottola, Intra-Ovarian Transplantation of Adipose-Derived MSCs: Clinical Trial Outcomes. Journal of Ovarian Research, 2021.

[27] Y. Martirosyan & Z. Zhang, Extracellular Vesicles in Treating DOR and POI: Preclinical & Clinical Updates. Life, 2023.

[28] J. Cho & W. Jiao, Placenta-Derived MSCs Promote Vascular Remodeling and Ovarian Restoration. Laboratory Investigation, 2020,S 304–317.

[29] S. Ali & R. Patel, Stem Cell-Based Therapeutic Strategies for POI & Infertility: Focus on Aging. Cells, 2022.

[30] L. Cacciottola & H. Liu, Mesenchymal Stem Cells to Enhance Fertility Potential. Human Reproduction Open, 2023.

[31] Z. Chen & Z. Fang, Stem Cell Therapies for Ovarian Failure: Clinical Advances. Reproductive Medicine & Biology, 2022, 110–119.

[32] Y. Zafardoust & M. Mashayekhi, Autologous Menstrual Blood-Derived MSCs for Ovarian Rejuvenation and Pregnancy Outcomes. Stem Cell Research & Therapy, 2023.

[33] H. Liu & T. Kim, Human Amnion-Derived MSCs in DOR: Preclinical and Translational Evidence. Stem Cell Research & Therapy, 2021.

[34] F. Fàbregues & J. Cho, In Vitro Follicular Activation & MSC Therapy for POI. Frontiers in Endocrinology, 2021.

[35] N. Pellicer & S. Herraiz, Ovarian Rescue Strategies in Women with POI. Reproductive Biomedicine Online, 2022, 91–103.

[36] N. Singh & J. Liu, TAMSCOT Clinical Trial: Autologous Marrow-Derived Stem Cell Ovarian Transplant. Human Reproduction, 2021.

[37] O. Falade, The feasibility of stem cell–based fertility treatments in low-resource settings. Global Health Research and Policy, 2022, 45–56.

[38] M. Mashayekhi & L. Cacciottola, Autologous Adipose-Derived MSC Transplantation for Idiopathic POF. Journal of Ovarian Research, 2021.

[39] E. Omotayo & T. Balogun, Reproductive biotechnology in Nigeria: Opportunities and challenges. Nigerian Journal of Biotechnology, 2022, 81–90.

[40] T. Bello, Regenerative medicine in African biomedical research: Emerging trends. Pan African Medical Journal, 2023, 132–148.

[41] S. Ndlovu & T. Moyo, Decolonizing biomedical research in Africa: Beyond participant inclusion. African Health Sciences, 2024, 44–58.

[42] A. Makker & A. Dravid, New Horizons in Ovarian Regeneration, Journal of Clinical Medicine, 2021, 3594.

[43] A. Wdowiak, K. Bak & A. Makara-Studzińska, Stem Cell-Based Therapies in Human Reproduction, International Journal of Molecular Sciences, 2021, 5094.

[44] A. Rodríguez, M.L. Liu & K.R. Peters, Stem Cells and Reproductive Aging: A Roadmap Towards Ovarian Rejuvenation, Aging Cell, 2021, e13317.

[45] D.A. Dumesic & D.H. Abbott, Implications of Polycystic Ovary Syndrome on Reproductive Health Across the Lifespan, Nature Reviews Endocrinology, 2012, 206–216.

[46] D.B. Seifer, R.S. MacLaughlin & C.M. Christian, AMH as a Prognostic Marker in IVF/ICSI Cycles, Fertility & Sterility, 2011, 1570–1574.

[47] D. Boothe, K. Schulz & L.M. Roberts, PRP and Stem Cell Therapies in the Treatment of Poor Ovarian Response, Reproductive Sciences, 2021, 811–820.

[48] ESHRE, Guideline Group on POI, Management of Women with Premature Ovarian Insufficiency, Human Reproduction Open, 2022, 030.

[49] F.R. Tehrani, F. Solaymani-Dodaran & M. Azizi, Factors Influencing AMH Levels in Women, Reproductive Biology & Endocrinology, 2010, 37.

[50] H. Gabr, R. Mahmoud, D. Aly & N.S. El-Gendy, Clinical Effects of Platelet-Rich Plasma on Ovarian Function in Premature Ovarian Insufficiency Patients, Journal of Ovarian Research, 2020, 115–121.

@article{1714914,
      author = {Ozor Victor Oluwaseun, Dr Omonike C bakare},
      title = {Ovarian Rejuvenation in Infertile Women with Low Anti-Müllerian Hormone Using Peripheral Blood–Derived Stem Cell Techniques},
      journal = {Iconic Research And Engineering Journals},
      year = {2026},
      volume = {9},
      number = {9},
      pages = {561-564},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1714914.pdf},
      abstract = {Diminished ovarian reserve (DOR) represents a major contributor to female infertility and is often characterized by reduced levels of anti-Müllerian hormone (AMH) and impaired folliculogenesis. This study evaluates the therapeutic efficacy of peripheral blood–derived stem cell (PBSC) therapy in restoring ovarian function and improving fertility outcomes in women presenting with low AMH levels. A cross-sectional study was conducted involving sixty participants divided equally into control and intervention groups at Vine Branch Fertility Centre, Ibadan, Nigeria. Peripheral blood samples (16 mL) were collected and processed via differential centrifugation to isolate the buffy coat containing stem and progenitor cells. The concentrated PBSC preparation was subsequently administered through intraovarian injection under ultrasound guidance. Anthropometric and biochemical parameters including AMH, follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, and antral follicle count (AFC) were evaluated. Statistical analysis was performed using SPSS with a significance level set at p < 0.05. Results demonstrated significant improvement in ovarian reserve markers in the intervention group, with AMH levels nearly doubling and AFC increasing substantially compared to controls. These findings suggest that PBSC therapy may promote ovarian rejuvenation through angiogenic signaling, stromal remodeling, and paracrine mechanisms.},
      keywords = {Ovarian Rejuvenation, Peripheral Blood Stem Cells, Anti-Müllerian Hormone, Infertility, Ovarian Reserve, Regenerative Medicine},
      month = {March},
      doi = {https://doi.org/10.64388/IREV9I9-1714914}
  }